Strikingly, a recent phase I clinical trial in patients with advanced cancers confirmed that dual blockade of both PI3K/AKT/mTOR and MEK/ERK pathways resulted in more favourable efficacy compared to single blockade of either pathway [31]. Here, MTOR is linked to cancer.